Design Therapeutics, Inc. (DSGN) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 58.78M USD | Research and Development Expense |
| Revenue | 0.00 USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 14.82M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -79.36M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $58.78M | $0.00 | $14.82M | $-79.36M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $58.13M | $0.00 | $14.93M | $-78.75M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $59.13M | $0.00 | $14.55M | $-79.47M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $57.86M | (m) | $14.59M | $-77.99M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $55.15M | (m) | $14.11M | $-74.93M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $49.93M | (m) | $13.43M | $-68.40M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $44.35M | $0.00 | $13.07M | $-62.38M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $43.20M | (m) | $12.32M | $-60.81M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $44.59M | (m) | $12.43M | $-63.39M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $51.13M | (m) | $12.85M | $-70.94M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $57.06M | (m) | $13.09M | $-78.19M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $60.31M | (m) | $13.44M | $-82.46M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $61.35M | (m) | $13.09M | $-82.83M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $55.58M | (m) | $11.99M | $-75.87M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $48.61M | (m) | $10.93M | $-67.59M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $41.70M | (m) | $9.40M | $-59.33M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $35.93M | (m) | $7.78M | $-51.47M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $29.66M | (m) | $6.40M | $-43.52M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $24.78M | (m) | $4.69M | $-35.83M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $6.06M | $226.00K | $450.00K | $-8.33M | (m) | 2681.42% | 199.12% | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |